FDA Approval Alert: The Need-to-Know | Taletrectinib in Locally Advanced or Metastatic ROS1+ NSCLC

In June 2025, the FDA approved taletrectinib for patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC
Podcast
Jul 14, 2025 12:00 PM
According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Advances in NSCLC Bring Excitement in the Lung Space
Video
Jul 4, 2025 6:00 PM
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
Taletrectinib Shows Positive Efficacy and Toxicity in ROS1+ NSCLC
Video
Jul 3, 2025 10:00 PM
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Taletrectinib Is Suitable for First- and Second-Line ROS1+ NSCLC
Video
Jul 2, 2025 10:00 PM
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.
Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC Therapies
Article
Jun 25, 2025 6:00 PM
Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.
Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.
FDA Approves Taletrectinib in ROS1+ NSCLC
Article
Jun 11, 2025 5:08 PM
Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.